1. 

   3 months ago

   Novo Nordisk's new obesity drug data disappoints again, shares fall

   Reuters
2. 

   3 months ago

   Novo Nordisk's Stock Dips: CagriSema Trial Results Shock Investors!

   WealthyBusiness
3. 

   6 months ago

   BMO’s Evan David Seigerman cuts Novo Nordisk price target after Cagrisema data disappoints

   Rif News
4. 

   2 months ago

   INJECTABLE WEAKNESSES: NOVO NORDISK

   RealAmericasVoice
5. 

   6 months ago

   BMO’s Evan David Seigerman cuts Novo Nordisk price target after Cagrisema data disappoints

   QuickSparkNews
6. 

   6 months ago

   BMO’s Evan David Seigerman cuts Novo Nordisk price target after Cagrisema data disappoints

   Citizen News
7. 

   6 months ago

   BMO’s Evan David Seigerman cuts Novo Nordisk price target after Cagrisema data disappoints

   EchoCurrent
8. 

   6 months ago

   BMO’s Evan David Seigerman cuts Novo Nordisk price target after Cagrisema data disappoints

   PulsePoint News
9. 

   6 months ago

   Novo Nordisk stock plunges on obesity shot trial results

   QuickSparkNews
10. 

    6 months ago

    Novo Nordisk stock plunges on obesity shot trial results

    HorizonReport
11. 

    6 months ago

    Novo Nordisk stock plunges on obesity shot trial results

    EchoCurrent
12. 

    6 months ago

    Novo Nordisk Selloff Is an Overreaction, Barclays' Field Says

    QuickSparkNews
13. 

    6 months ago

    Novo Nordisk Selloff Is an Overreaction, Barclays' Field Says

    HorizonReport
14. 

    5 months ago

    Novo Nordisk's New Obesity Drug: Game Changer? #shorts

    WealthyBusiness
15. 

    9 months ago

    Senate HELP committee grills Novo Nordisk on weight loss drug pricing - September 24, 2024

    R.C. Davis